These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 32282971)

  • 1. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
    Milani P; Fazio F; Basset M; Berno T; Larocca A; Foli A; Riva M; Benigna F; Oliva S; Nuvolone M; Rodigari L; Petrucci MT; Merlini G; Palladini G
    Am J Hematol; 2020 Aug; 95(8):900-905. PubMed ID: 32282971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
    Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
    Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
    Bellofiore C; Benvenuti P; Mina R; Basset M; Foli A; Nanci M; Nuvolone M; Guida G; Attanasio A; Mussinelli R; Mangiacavalli S; Cartia CS; Masoni V; Palumbo M; Cani L; Oliva S; Consoli U; Conticello C; Di Raimondo F; Arcaini L; Bringhen S; Merlini G; Palladini G; Milani P
    Hematol Oncol; 2024 Jul; 42(4):e3289. PubMed ID: 38824453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
    Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
    Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
    [No Abstract]   [Full Text] [Related]  

  • 5. Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regime.
    Bomsztyk J; Ravichandran S; Khwaja J; Cohen O; Rauf MU; Foard D; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore J; Lachmann H; Mahmood S; Wechalekar AD
    Br J Haematol; 2024 Jul; 205(1):138-145. PubMed ID: 38840512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
    N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].
    Shen KN; Miao HL; Gao YJ; Cao XX; Zhou DB; Su W; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):31-34. PubMed ID: 35231990
    [No Abstract]   [Full Text] [Related]  

  • 9. Options for Rescue Treatment of Patients with AL Amyloidosis Exposed to Upfront Daratumumab.
    Bellofiore C; Palladini G; Milani P
    Curr Oncol Rep; 2024 Sep; 26(9):1097-1103. PubMed ID: 38896184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
    Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
    Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
    Lecumberri R; Krsnik I; Askari E; Sirvent M; González-Pérez MS; Escalante F; Pradillo V; Tamariz LE; Cánovas V; Alegre A; Gironella M; González-García ME; Infante MS; Lakhwani S; Martínez-Bilbao C; Dourdil V; Ramírez-Payer Á; Sarrá J; Cibeira MT
    Amyloid; 2020 Sep; 27(3):163-167. PubMed ID: 32106714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
    Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL
    Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
    Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
    Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
    Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
    Palladini G; Milani P; Malavasi F; Merlini G
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
    Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
    Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab for the treatment of AL amyloidosis.
    Sidiqi MH; Gertz MA
    Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
    Ehsan H; Rafae A; Masood A; Wahab A; Sana MK; Ansar I; Neupane K; Umar A; Ehsan A; Hashmi H
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e285-e292. PubMed ID: 34879994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
    Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
    Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.